Antidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: In vivo approach

Biomed Pharmacother. 2016 Dec:84:230-236. doi: 10.1016/j.biopha.2016.09.039. Epub 2016 Sep 20.

Abstract

P-coumaric acid (p-CA, 3-[4-hydroxyphenyl]-2-propenoic acid), the major component widely found in nutritious plant foods, has various antioxidant, antiinflammatory and anticancer property. To evaluate the antidiabetic and antihyperlipidemic mechanisms, via the effects on carbohydrate, lipids and lipoproteins responses in adult male albino Wistar rats were examined by treated with p-CA. Rats were injected with streptozotocin (STZ, 40mg/kg b.w.) by intraperitonially (i.p.) 30days for the induction of experimental diabetes mellitus. Diabetic rats were treated with p-CA orally at a dose of 100mg/kg b.w. The potential defending character of p-CA against diabetic rats was evaluated by performing the various biochemical parameters and glucose transporter such as GLUT2 mRNA expression of pancreas. Administration of p-CA significantly lowers the blood glucose level, gluconeogenic enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase whereas increases the activities of hexokinase, glucose-6 phosphatase dehydrogenase and GSH via by increasing level of insulin. p-CA reduces the total cholesterol and triglycerides in both plasma and tissues i.e. liver and kidney. p-CA also decreases the LDL-C, VLDL-C and it considerably increase the level of HDL-C. A significant decreased expression of GLUT 2 mRNA in the pancreas was recorded in the supplementation of p-CA treated groups. Taken together, these results suggest that p-CA modulates glucose and lipid metabolism via GLUT 2 activation in the pancreatic and has potentially beneficial effects in improving or treating metabolic disorders.

Keywords: Carbohydrate metabolic enzyme; Diabetes mellitus; GLUT 2; Lipid; Streptozotocin; p-Coumaric acid.

MeSH terms

  • Animals
  • Biomarkers / blood
  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Coumaric Acids / pharmacology*
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Down-Regulation
  • Glucose Transporter Type 2 / drug effects*
  • Glucose Transporter Type 2 / genetics
  • Glucose Transporter Type 2 / metabolism
  • Glutathione / metabolism
  • Hypoglycemic Agents / pharmacology*
  • Hypolipidemic Agents / pharmacology*
  • Insulin / blood
  • Kidney / drug effects
  • Kidney / metabolism
  • Lipids / blood*
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Pancreas / drug effects*
  • Pancreas / metabolism
  • Propionates
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats, Wistar
  • Streptozocin

Substances

  • Biomarkers
  • Blood Glucose
  • Coumaric Acids
  • Glucose Transporter Type 2
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Insulin
  • Lipids
  • Propionates
  • RNA, Messenger
  • Slc2a2 protein, rat
  • Streptozocin
  • Glutathione
  • p-coumaric acid